Next Article in Journal
Value Added Medicines: What Value Repurposed Medicines Might Bring to Society?
Previous Article in Journal
Determining the Value of Medical Technologies to Treat Ultra-Rare Disorders: A Consensus Statement
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 4
Issue 1
10.3402/jmahp.v4.33177
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

What Makes a Compliant Phase III and Pre-launch Patient Advocacy Strategy?

by
Nick Hicks
1,*,
Keith Allan
2,
Christoph Thalheim
3 and
Paul Woods
4
1
Commutateur Advocacy Communications, C/O Destination Conseil 16 Rue Pierre Fontaine, FR-75009 Paris, France
2
Medical and Pharmaceutical Consultant, Leicester, UK
3
European Multiple Sclerosis Platform, Brussels, Belgium
4
Paul Woods Compliance, Stockport, UK
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2016, 4(1), 33177; https://doi.org/10.3402/jmahp.v4.33177
Submission received: 17 August 2016 / Revised: 3 November 2016 / Accepted: 8 November 2016 / Published: 13 December 2016

Abstract

Background: A key task for the pharmaceutical industry is to understand the compliance implications of engaging with a patient advocacy group (PAG). This presents challenges for the industry to negotiate the ethical and reputational issues that can arise when working with a PAG. Objective: To gain the views of pharmaceutical industry executives on future compliance challenges when working with PAGs. Study design: We conducted two surveys among two sets of industry executives: one group focussed on market access roles and the other focussed on non-market access roles. Results: Transparency was identified as the biggest challenge, followed by project rationale and then by project ownership. Conclusion: We explore how this can be overcome and make recommendations on how best to work compliantly with PAGs.
Keywords: pharmaceutical industry; patient advisory group; transparency; compliance; ethics; reputation pharmaceutical industry; patient advisory group; transparency; compliance; ethics; reputation

Share and Cite

MDPI and ACS Style

Hicks, N.; Allan, K.; Thalheim, C.; Woods, P. What Makes a Compliant Phase III and Pre-launch Patient Advocacy Strategy? J. Mark. Access Health Policy 2016, 4, 33177. https://doi.org/10.3402/jmahp.v4.33177

AMA Style

Hicks N, Allan K, Thalheim C, Woods P. What Makes a Compliant Phase III and Pre-launch Patient Advocacy Strategy? Journal of Market Access & Health Policy. 2016; 4(1):33177. https://doi.org/10.3402/jmahp.v4.33177

Chicago/Turabian Style

Hicks, Nick, Keith Allan, Christoph Thalheim, and Paul Woods. 2016. "What Makes a Compliant Phase III and Pre-launch Patient Advocacy Strategy?" Journal of Market Access & Health Policy 4, no. 1: 33177. https://doi.org/10.3402/jmahp.v4.33177

APA Style

Hicks, N., Allan, K., Thalheim, C., & Woods, P. (2016). What Makes a Compliant Phase III and Pre-launch Patient Advocacy Strategy? Journal of Market Access & Health Policy, 4(1), 33177. https://doi.org/10.3402/jmahp.v4.33177

Article Metrics

Back to TopTop